Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell E Lewis

Showing results (1-10 of 225) with videos related to

Pageof 23
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
What is the "therapeutic range" for voriconazole?Russell E Lewis
Current Opinion in Pharmacology|July 10, 2007
Pharmacodynamic implications for use of antifungal agentsRussell E Lewis
Pharmacotherapy|May 24, 2006
Decision making in antifungal monotherapy versus combination therapyRussell E Lewis
Expert Opinion on Pharmacotherapy|August 2, 2002
Pharmacotherapy of Candida bloodstream infections: new treatment options, new eraRussell E Lewis
Mayo Clinic Proceedings|August 2, 2011
Current concepts in antifungal pharmacologyRussell E Lewis
Virulence|September 6, 2016
Using carbapenems for carbapenem-resistant Klebsiella pneumoniae-Are we flogging a dead (work)horse antibiotic?Russell E Lewis
American Journal of Therapeutics|January 21, 2011
Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infectionsRussell E Lewis
Journal of Fungi (Basel, Switzerland)|June 26, 2024
The Impact of Dimitrios P. Kontoyiannis on Mucormycosis ResearchRussell E Lewis
Medical Mycology|November 10, 2018
Managing drug interactions in the patient with aspergillosisRussell E Lewis
Current Medical Research and Opinion|June 13, 2009
Overview of the changing epidemiology of candidemiaRussell E Lewis
Pageof 23

Showing results (1-10 of 225) with videos related to

Sort By:
Pageof 23
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
What is the "therapeutic range" for voriconazole?Russell E Lewis
Current Opinion in Pharmacology|July 10, 2007
Pharmacodynamic implications for use of antifungal agentsRussell E Lewis
Pharmacotherapy|May 24, 2006
Decision making in antifungal monotherapy versus combination therapyRussell E Lewis
Expert Opinion on Pharmacotherapy|August 2, 2002
Pharmacotherapy of Candida bloodstream infections: new treatment options, new eraRussell E Lewis
Mayo Clinic Proceedings|August 2, 2011
Current concepts in antifungal pharmacologyRussell E Lewis
Virulence|September 6, 2016
Using carbapenems for carbapenem-resistant Klebsiella pneumoniae-Are we flogging a dead (work)horse antibiotic?Russell E Lewis
American Journal of Therapeutics|January 21, 2011
Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infectionsRussell E Lewis
Journal of Fungi (Basel, Switzerland)|June 26, 2024
The Impact of Dimitrios P. Kontoyiannis on Mucormycosis ResearchRussell E Lewis
Medical Mycology|November 10, 2018
Managing drug interactions in the patient with aspergillosisRussell E Lewis
Current Medical Research and Opinion|June 13, 2009
Overview of the changing epidemiology of candidemiaRussell E Lewis
Pageof 23